There is growth in manufacturing sterile injectable drugs and a trend toward using prefilled syringes. India's Gland Pharma does both, and investment group KKR finds that an enticing proposition. KKR India has taken a minority stake in the drugmaker, investing $200 million, buying out the entire stake held by Evolvence India Life Sciences Fund.
It's the time of year when the days are short and dark, bears are hibernating, fires are burning and people are exclaiming, "Where did the year go?" Alas, we can't answer that question. What we can offer are a few hints about how the year went. Five hints, to be exact, in the form of FiercePharma's 5 best-read stories of 2013.
The Obama administration says Medicare drug discounts have saved U.S. recipients $8.9 billion so far in prescription drug costs. Of course, the more they save, the less drugmakers earn, since they are the ones having to pony up the discounts, which the Obama administration is looking to make even larger.
Drugmaker GlaxoSmithKline is sending R&D folks into new areas to look for drugs, launching satellite innovation centers in Cambridge, MA, and San Diego.
Teva Pharmaceutical Industries hasn't had much good news to share lately. Today, it had a little something to crow about: The FDA has granted orphan status to its cancer-fighting drug, Treanda.
Most drugmakers say mergers are what they need to become bigger and more profitable. South Africa's Adcock Ingram say it needs a proposed merger just to survive.
FDA Commissioner Margaret Hamburg is slated to travel to India soon, and she will have lots to talk about--like all of the Indian plants the FDA has banned from exporting to the U.S. The agency Tuesday hit a second Wockhardt facility with a so-called import alert that prevents it from selling products into the U.S.
Italian drugmaker Menarini is looking to grow its operations in India. It is bringing some new products to market there but would like to buy some established drug brands if it can find them at the right price.
A morning-after contraceptive pill sold in Europe may not work in women who weigh more than 176 pounds, regulators there said, triggering an FDA review of Teva Pharmaceutical's PlanB One-Step product and its generic versions.
A new study in JAMA Pediatrics finds that sex and money each play a role in U.S. parents' reluctance to vaccinate their children against the human papillomavirus. But a lack of easy-to-understand information about the shots--and often, the lack of a doctor's clear recommendation for them--are also helping to depress vaccination rates.
Two buyout firms are duking it out for LTS Lohmann, a drug-patch maker partly owned by Novartis, Reuters reports. Now that the dust has settled on first-round bids, which were due last month, Wendel and Nordic Capital are still in the running for a deal worth about $1.6 billion.
When Bayer CEO Marijn Dekkers stepped into the job in 2010, he had a trove of cash, and he promised to spend a big chunk on deals. A $23 billion chunk, in fact. Since then, the German conglomerate hasn't exactly been audacious in the M&A arena. Bayer has snapped up a healthcare company or three, but it's quick to back away if a price gets too rich.
The FDA did a hard about-face today on GlaxoSmithKline's diabetes drug Avandia, deciding that the drug presents no more heart risk than the most commonly used Type 2 diabetes drugs and withdrawing the label warnings and other restrictions.
Mylan said today that it and Indian biologics partner Biocon have nabbed the first approval in India and will have a biosimilar of Herceptin (trastuzumab) ready to roll out early next year.
After Novartis's investor day, the spotlight quickly moved to the company's $5 billion buyback plan. CEO Joe Jimenez and his team also unveiled some details--a few, at least--about the company's strategic review.
Gilead Sciences' new hepatitis C drug sofosbuvir won preliminary backing from European regulators on Friday, with marketing approval expected to follow soon. The FDA is expected to clear the drug for take-off Dec. 8, if not sooner. All good for the California-based drugmaker. But there's a battle over sofosbuvir brewing in India.
Johnson & Johnson won FDA approval for Olysio (simeprevir), its drug to treat hepatitis C, in combination with standard treatments interferon and ribavirin.
Teva's best-selling drug Copaxone will face generic competition next year, fully 18 months before the company had anticipated. That's gonna hurt. How much will it hurt? An Israeli publication thinks it has Teva's answer to that--a 42% cut to the drug's sizable profits.
Which drugmakers are likely to be the biggest dealmakers of 2014? The direct evidence is trickling in. Sanofi CEO Chris Viehbacher, for instance, says he's looking to spend up to €2 billion on deals next year, or about $2.7 billion.
The FDA has approved its first adjuvanted vaccine against a potential outbreak of the deadly bird flu. It just won't be available at the local pharmacy.